FDA approval is not clinical adoption

01 The chain

The approval is the first gate, not the last

Transcatheter aortic valve replacement took eight years from its first approval to the guideline that put the procedure in front of the low-risk population the later trials studied. No step failed. Each body answered its own question on its own clock.

Date	Body	Act	Population	State
2011-11-02	FDA	Premarket approval of the first transcatheter valve Approval letter	Severe aortic stenosis, patients who cannot undergo surgery	Closed
2012-05-01	CMS	National coverage determination NCD 20.32	Inoperable patients; other populations only inside a registry	Closed
2014-03	ACC/AHA	Valve guideline Guideline	Class I for inoperable patients; Class IIa for high-risk operable patients	Closed
2019-06	CMS	Coverage determination revised Revised NCD 20.32	Commercial coverage without the registry requirement	Open
2019-08	FDA	Label expansion Label	Low-risk operable patients	Open
2020-12	ACC/AHA	Valve guideline revision Guideline	Low-risk population	Open

Rows marked closed were superseded by a later act in the same chain. The dates are the publication dates of the documents, not the dates the decisions were made.

Our reading The approval is one gate in a longer chain, and the chain is the unit a launch plan should be built on. This case supports the reading.

02 The event

A positive trial is not an inflection

An anti-amyloid antibody met its primary endpoint in a trial of 1,795 patients over a year and a half. The advisory committee voted in favour, and the regulator converted an accelerated approval into a traditional one. Then the coverage body limited payment to patients enrolled in a registry. The approval happened; coverage did not follow, and the sponsor later discontinued the product.

None of those events was an inflection point. An inflection point is a change in the number of patients who can receive the therapy, and the last gate sets that number.

The regulator asks whether the product is safe and effective in the population studied. The payer asks whether it will pay for the label population, and under what conditions. The guideline asks where the therapy sits in a pathway. The site asks whether it can deliver the therapy to the patient the label describes.

A positive trial becomes a commercial inflection when five conditions hold at once. Each is observable before the launch, and each can fail independently.

Date	Body	Act	Population	State
2022-11-29	Trial sponsors	Pivotal trial published Trial paper	Early Alzheimer's disease, biomarker-confirmed	Open
2023-01-06	FDA	Accelerated approval Approval letter	Early Alzheimer's disease, biomarker-confirmed	Closed
2023-06-09	FDA advisory committee	Vote in favour Vote record	Early Alzheimer's disease, biomarker-confirmed	Open
2023-06-22	CMS	Coverage determination National Coverage Determination	Patients enrolled in a qualifying registry	Open
2023-07-06	FDA	Traditional approval Label	Early Alzheimer's disease, biomarker-confirmed	Open
—	Sites	Infusion and monitoring pathway Local protocol	Sites with confirmation testing, MRI monitoring and infusion capacity	Not reached

The last row has no date because no single document opens it. The local pathway opens site by site.

• The trial population matches the label population.
• The label population matches the coverage population.
• The covered population has a confirmation test, a monitoring schedule and a delivery pathway.
• The guideline places the therapy in a pathway, not only in a recommendation.
• The price and monitoring burden fit the payer's budget without a new authorization regime.

Our reading A positive trial changes the evidence layer; a commercial inflection requires the four gates that follow it, and they do not move together. The five conditions are a checklist, not a validated model. The last gate opens site by site, which is why no single document can date it.

03 The cutoff

What the record held at the cutoff

At the 2011 approval, the record held one gate: a device approved for patients who could not undergo surgery. Coverage, a guideline recommendation and a low-risk trial were still open questions. In the second case, the 2022 coverage decision left a covered population narrower than the label. A reconstruction says which cutoff it uses; a retrospective does not.

Our reading Before the coverage document exists, the population each gate covers is already visible in the label, the price and the delivery route.

Dates, acts and populations come from the named document; a study's population is the one it enrolled. A body's account of its own rule is a record of the account, consensus is a dated summary rather than a source, and "Our reading" marks interpretation, not a finding.

Bring the action and your deadline

Which decision matters to your team, and by what date? Include the population and the plan it would inform.

Ask about this guide